Search results
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 8 hours agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
How George Floyd’s Death Exposed a Fake Syndrome: ‘Excited Delirium’
Scientific American· 1 day agoOn May 25, 2020, George Floyd was arrested for allegedly using a counterfeit $20 bill to buy...
"Statistically, I Shouldn't Be Here" — 14 People Who Had A Slim Chance At Survival Are Sharing Their...
BuzzFeed via Yahoo News· 6 days agoFrom Ernest Shackleton and crew's 800-mile Antarctic journey to survival in 1915, to modern stories...
How relief pitcher John King significantly improved his sinker: Cardinals Extra
St. Louis Post-Dispatch· 6 days agoStatistically, Cardinals relief pitcher John King’s sinker has been markedly better this season than...
Missouri Republican governor’s race is close. What a new poll says about who’s ahead
Kansas City Star via AOL· 5 hours agoNow, Coats said, Kehoe and Ashcroft are statistically tied. Coats said Missouri conservatives were...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 16 hours agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
The past five years for Time Out Group (LON:TMO) investors has not been profitable
Simply Wall St. via Yahoo Finance· 2 days agoStatistically speaking, long term investing is a profitable endeavour. But no-one is immune from...
I went on 6 flights in 10 days — these $21 slippers kept me comfy and supported
Yahoo Life Shopping· 2 days agoReal talk: I hate flying. Nothing scares me more than hitting turbulence at 30,000 feet. I know, I...
FDA approves new drug to treat autoimmune liver disease: ‘Giant step forward’
Fox News· 10 hours agoA new drug to control liver disease has gotten the green light. The U.S. Food and Drug...
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
InvestorPlace· 8 hours agoSarepta Therapeutics (NASDAQ:SRPT) stock jumped about 30% overnight after the Food and Drug...